Perrigo Pegs Growth To Initiating OTC Switches, Not Following Brands' NDAs

"A foundation of this business has been," says Perrigo's Americas consumer business chief, Jeffrey Needham, "we are a fast follower. That's been our traditional model. We can't afford to do that going forward." In addition to initiating moving ingredients from Rx to OTC, firm is developing "national better brand" versions of drugs already available OTC.

two hands trying to connect couple puzzle piece with sunset background. Jigsaw alone wooden puzzle against sun rays. one part of whole. symbol of association and connection. business strategy.

Producing generics of OTC drug brands isn't enough for Perrigo Co. PLC any longer as it targets bigger growth and expects to get there marketing branded drugs, including developing its own Rx-to-OTC switches.

More from Rx-to-OTC Switch

Revenue Drain Among Challenges For ACNU OTC Marketers From Simultaneous Rx Availability

 

Final rule’s requirement that ACNU formulations also remain available as Rx generics could limit revenues for marketers of the nonprescription drugs while approvals of ACNU applications from studies with participants having drugs delivered to their homes may require marketers to limit distribution to direct-to-consumer without clearance for sales in retail stores.

Statin In Technology-Assisted OTC Study May Be First To Take ‘Fail-First’ Step For ‘ACNU’ Switch

 

Study completed in 2024 showed consumers using an online application accurately self-selected and safely used an Rx statin drug. An “ACNU” switch NDA would have to first show conventional OTC labeling won’t support proper self-selection and use.

US FDA Doesn’t Budge On ‘ACNU’ Switch Requirements Questioned By OTC Industry

 

Agency’s proposal for targeting making more formulations available nonprescription through “novel switches” went through changes on its path from idea in 2012 to proposed rule in 2022 and final rule published in December.

‘New Paradigm’ For US OTC Switches Dawns After More Than 12 Years With ‘ACNU’ Final Rule

 

FDA’s ‘ACNU’ rule went through numerous twists and turns from agency’s “new paradigm” idea of OTC switches in 2012 to publication.

More from Health

Ad Claims Relying On Product Test Questionnaires Must Reflect Wording – NAD

 

Anti-aging skin care device marketer UVVU Inc. agreed to discontinue or modify a number of claims for its SolaWave 4-in-1 Skin Care Wand with Red Light Therapy, since statements were not substantiated by an in-home use study on which they relied, says the National Advertising Division.

People On The Move: Appointments At Maxwellia, Reckitt, Barentz

 
• By 

A round-up of the latest European consumer health appointments: Maxwellia adds CFO and board member; Reckitt restructures operations; Barentz names CEO.

Statin In Technology-Assisted OTC Study May Be First To Take ‘Fail-First’ Step For ‘ACNU’ Switch

 

Study completed in 2024 showed consumers using an online application accurately self-selected and safely used an Rx statin drug. An “ACNU” switch NDA would have to first show conventional OTC labeling won’t support proper self-selection and use.